Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus - IM011-074

Updated: 14 May, 2019   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participants Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page IM011-074
Download Study Participants Guide

SELECT LANGUAGE

Trial Details

  • Phase 2

    Phase

  • Gender(s)

  • 18-75

    Age Range

  • 25

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: BMS-986165 Dose 1
Drug: BMS-986165
Experimental: BMS-986165 Dose 2
Drug: BMS-986165
Experimental: BMS-986165 Dose 3
Drug: BMS-986165

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug - Women of childbearing potential (WOCBP) must have a negative urine pregnancy test and must agree to use correctly a highly effective method(s) of contraception for the duration of treatment with study drug Exclusion Criteria: - Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason - Evidence of active tuberculosis (TB) Other protocol defined inclusion/exclusion criteria could apply

Have questions? Email Us

Have questions?
Email Us